A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

20152,495 citationsJournal Articlebronze Open Access

Authors

F. Xavier Pi‐Sunyer · Columbia University

Arne Astrup · University of Copenhagen

Ken Fujioka · Scripps Clinic

Frank L. Greenway · Louisiana State University System

Alfredo Halpern · Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Michel Krempf · Centre Hospitalier Universitaire de Nantes

David C.W. Lau

Abstract

In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control. (Funded by Novo Nordisk; SCALE Obesity and Prediabetes NN8022-1839 ClinicalTrials.gov number, NCT01272219.).

Topics & Keywords

Diabetes Treatment and Management Pharmacology and Obesity Treatment Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 1, pp. 11-22

DOI: 10.1056/nejmoa1411892

Field-Weighted Citation Impact: 102.02